Literature DB >> 9597553

Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies.

J B Post1, W H Frishman.   

Abstract

Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, the drug causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Its pharmaco-dynamics are reviewed in this article, along with the clinical experiences in patients with hypertensive urgencies and emergencies. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam influsion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597553     DOI: 10.1002/j.1552-4604.1998.tb04369.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Lengthening primary cilia enhances cellular mechanosensitivity.

Authors:  M Spasic; C R Jacobs
Journal:  Eur Cell Mater       Date:  2017-02-20       Impact factor: 3.942

2.  G protein-coupled receptor kinase 4 gene variants in human essential hypertension.

Authors:  Robin A Felder; Hironobu Sanada; Jing Xu; Pei-Ying Yu; Zheng Wang; Hidetsuna Watanabe; Laureano D Asico; Wei Wang; Shaopeng Zheng; Ikuyo Yamaguchi; Scott M Williams; James Gainer; Nancy J Brown; Debra Hazen-Martin; Lee-Jun C Wong; Jean E Robillard; Robert M Carey; Gilbert M Eisner; Pedro A Jose
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 3.  Treatment of hypertensive urgencies and emergencies.

Authors:  C Venkata S Ram; Russell L Silverstein
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

4.  Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome.

Authors:  Gianluigi Ardissino; Antenore Giussani; Valentina Capone; Sara Testa; Cristiano Gandini; Giovanni Montini
Journal:  Pediatr Nephrol       Date:  2021-05-17       Impact factor: 3.714

5.  Pharmacokinetics And Pharmacodynamics Of Fenoldopam Mesylate For Blood Pressure Control In Pediatric Patients.

Authors:  Gregory B Hammer; Susan T Verghese; David R Drover; Myron Yaster; Joseph R Tobin
Journal:  BMC Anesthesiol       Date:  2008-10-06       Impact factor: 2.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.